Cargando…

The Development of Multiple Periprosthetic Joint Infections in Conjunction With Ibrutinib Therapy

Periprosthetic joint infections (PJI) can be subcategorized into acute postoperative infections, occurring within three months of implantation, and delayed onset infections, occurring after three months of implantation. PJIs can be caused by numerous infectious etiologies. Here, we describe a unique...

Descripción completa

Detalles Bibliográficos
Autores principales: Muttana, Swathi, Solowiej Singh, Christopher, Kim, Harim, Smith, Christopher J, Michael, Miriam B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783636/
https://www.ncbi.nlm.nih.gov/pubmed/35103201
http://dx.doi.org/10.7759/cureus.20639
_version_ 1784638576127901696
author Muttana, Swathi
Solowiej Singh, Christopher
Kim, Harim
Smith, Christopher J
Michael, Miriam B
author_facet Muttana, Swathi
Solowiej Singh, Christopher
Kim, Harim
Smith, Christopher J
Michael, Miriam B
author_sort Muttana, Swathi
collection PubMed
description Periprosthetic joint infections (PJI) can be subcategorized into acute postoperative infections, occurring within three months of implantation, and delayed onset infections, occurring after three months of implantation. PJIs can be caused by numerous infectious etiologies. Here, we describe a unique case of a patient with a history of bilateral shoulder and knee replacements over five years. The patient received a diagnosis of Waldenströms macroglobulinemia five years before her admission but deferred ibrutinib treatment until one year before her admission. We believe that the timeline coincides with the development of multiple PJIs secondary to ibrutinib therapy. The patient presented with bilateral shoulder and knee pain and swelling, following a flu-like illness that had resolved one year before the admission. Her joint symptoms did not subside along with the remaining flu-like symptoms. Initially, her symptoms served as clues to the diagnosis; however, the diagnosis was finally made and supported by joint aspiration. The patient was treated with vancomycin 1.25 g in sodium chloride 0.9% 250 mL intravenous piggyback every 24 hours for the treatment of PJI and oral daptomycin 500 mg daily for six weeks as prophylaxis for PJI. In conclusion, physicians need to consider the development of PJIs when prescribing immunosuppressive therapy, as well as an early diagnosis to prevent further complications.
format Online
Article
Text
id pubmed-8783636
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-87836362022-01-30 The Development of Multiple Periprosthetic Joint Infections in Conjunction With Ibrutinib Therapy Muttana, Swathi Solowiej Singh, Christopher Kim, Harim Smith, Christopher J Michael, Miriam B Cureus Internal Medicine Periprosthetic joint infections (PJI) can be subcategorized into acute postoperative infections, occurring within three months of implantation, and delayed onset infections, occurring after three months of implantation. PJIs can be caused by numerous infectious etiologies. Here, we describe a unique case of a patient with a history of bilateral shoulder and knee replacements over five years. The patient received a diagnosis of Waldenströms macroglobulinemia five years before her admission but deferred ibrutinib treatment until one year before her admission. We believe that the timeline coincides with the development of multiple PJIs secondary to ibrutinib therapy. The patient presented with bilateral shoulder and knee pain and swelling, following a flu-like illness that had resolved one year before the admission. Her joint symptoms did not subside along with the remaining flu-like symptoms. Initially, her symptoms served as clues to the diagnosis; however, the diagnosis was finally made and supported by joint aspiration. The patient was treated with vancomycin 1.25 g in sodium chloride 0.9% 250 mL intravenous piggyback every 24 hours for the treatment of PJI and oral daptomycin 500 mg daily for six weeks as prophylaxis for PJI. In conclusion, physicians need to consider the development of PJIs when prescribing immunosuppressive therapy, as well as an early diagnosis to prevent further complications. Cureus 2021-12-23 /pmc/articles/PMC8783636/ /pubmed/35103201 http://dx.doi.org/10.7759/cureus.20639 Text en Copyright © 2021, Muttana et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Muttana, Swathi
Solowiej Singh, Christopher
Kim, Harim
Smith, Christopher J
Michael, Miriam B
The Development of Multiple Periprosthetic Joint Infections in Conjunction With Ibrutinib Therapy
title The Development of Multiple Periprosthetic Joint Infections in Conjunction With Ibrutinib Therapy
title_full The Development of Multiple Periprosthetic Joint Infections in Conjunction With Ibrutinib Therapy
title_fullStr The Development of Multiple Periprosthetic Joint Infections in Conjunction With Ibrutinib Therapy
title_full_unstemmed The Development of Multiple Periprosthetic Joint Infections in Conjunction With Ibrutinib Therapy
title_short The Development of Multiple Periprosthetic Joint Infections in Conjunction With Ibrutinib Therapy
title_sort development of multiple periprosthetic joint infections in conjunction with ibrutinib therapy
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783636/
https://www.ncbi.nlm.nih.gov/pubmed/35103201
http://dx.doi.org/10.7759/cureus.20639
work_keys_str_mv AT muttanaswathi thedevelopmentofmultipleperiprostheticjointinfectionsinconjunctionwithibrutinibtherapy
AT solowiejsinghchristopher thedevelopmentofmultipleperiprostheticjointinfectionsinconjunctionwithibrutinibtherapy
AT kimharim thedevelopmentofmultipleperiprostheticjointinfectionsinconjunctionwithibrutinibtherapy
AT smithchristopherj thedevelopmentofmultipleperiprostheticjointinfectionsinconjunctionwithibrutinibtherapy
AT michaelmiriamb thedevelopmentofmultipleperiprostheticjointinfectionsinconjunctionwithibrutinibtherapy
AT muttanaswathi developmentofmultipleperiprostheticjointinfectionsinconjunctionwithibrutinibtherapy
AT solowiejsinghchristopher developmentofmultipleperiprostheticjointinfectionsinconjunctionwithibrutinibtherapy
AT kimharim developmentofmultipleperiprostheticjointinfectionsinconjunctionwithibrutinibtherapy
AT smithchristopherj developmentofmultipleperiprostheticjointinfectionsinconjunctionwithibrutinibtherapy
AT michaelmiriamb developmentofmultipleperiprostheticjointinfectionsinconjunctionwithibrutinibtherapy